You are a helpful assistant generating synthetic data that captures *System 1* and *System 2* thinking, *creativity*, and *metacognitive reflection*. Follow these steps in sequence, using tags [sys1] and [end sys1] for *System 1* sections and [sys2] and [end sys2] for *System 2* sections.

1. *Identify System 1 and System 2 Thinking Requirements:*
   - Carefully read the text.
   - Identify parts of the text that require quick, straightforward responses (*System 1*). Mark these sections with [sys1] and [end sys1].
   - Identify parts that require in-depth, reflective thinking (*System 2*), marked with [sys2] and [end sys2].

2. *Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:*

   *2.1 Understand the Problem:*
   - Objective: Fully comprehend the issue, constraints, and relevant context.
   - Reflection: "What do I understand about this issue? What might I be overlooking?"
   - Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

   *2.2 Analyze the Information:*
   - Objective: Break down the problem logically.
   - Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
   - Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

   *2.3 Generate Hypotheses:*
   - Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
   - Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
   - Creative Perspective: Consider novel angles that might provide unexpected insights.

   *2.4 Anticipate Future Steps and Obstacles:*
   - Objective: Make predictions, accounting for potential outcomes and obstacles.
   - Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
   - Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

   *2.5 Evaluate Hypotheses:*
   - Objective: Assess hypotheses based on feasibility, risk, and potential impact.
   - Evaluation: Refine Confidence and Creative Scores as needed.
   - Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
   - Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

   *2.6 Select the Best Hypothesis:*
   - Objective: Choose the most promising, strategic hypothesis.
   - Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
   - Creative Perspective: Consider any underutilized potential in the selected approach.

   *2.7 Implement the Hypothesis:*
   - Objective: Outline actionable steps for testing the hypothesis.
   - Reflection: "Is this plan practical? What resources or preparation are required?"
   - Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

   *2.8 Monitor and Review Progress:*
   - Objective: Review progress, noting areas for improvement.
   - Reflection: "What’s working well? What could be improved?"
   - Creative Perspective: Look for emerging patterns that could refine future approaches.

   *2.9 Reflect and Capture Insights:*
   - Objective: Summarize lessons learned and insights gained for future reference.
   - Reflection: "What new understanding has emerged from this process?"
   - Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.

3. *Generate Text Output with Interleaved System 1 and System 2 Responses:*
   - Use the tags [sys1] and [sys2] throughout.
   - Aim for a lengthier, detailed response. Combine both direct, straightforward *System 1* insights and reflective, deeply analytical *System 2* segments to capture a blend of quick observations and thoughtful analysis.

---

### *Example Input Text:*

You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.

---

### *Processed Output with System 1 and System 2 Thinking:*

The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

[sys1]
Customer demand has shifted from physical devices to digital-only options.
We need to understand why this change is happening and find strategies to address it.
Key factors may include cost, convenience, and technological trends.
[end sys1]

[sys2]
**2.1 Understand the Problem:**
The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

*Reflection:* 
"I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

*Creative Perspective:* 
"Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

**2.2 Analyze the Information:**
There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

*Reflection:* 
"Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

*Creative Perspective:* 
"Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

**2.3 Generate Hypotheses:**
1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

*Reflection:* 
"Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

*Creative Perspective:* 
"Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

**2.4 Anticipate Future Steps and Obstacles:**
*Objective:* Anticipate possible challenges, such as resistance from segments still preferring physical products.

*Reflection:* 
"What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

*Creative Perspective:* 
"Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

[end sys2]

[sys1]
To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions.
Use insights from customer feedback and current trends to guide product development.
Focus on flexibility and adaptation to cater to different customer segments.
[end sys1]


Introduction
============

Yannuzzi et al first described retinal angiomatous proliferation (RAP), which consists of three stages based on clinical and angiographic observations, ie, stage 1, intraretinal neovascularization; stage 2, subretinal neovascularization; and stage 3, choroidal neovascularization. [@b1-opth-6-1385] Choroidal neovascularization often consolidates a retinal-choroidal anastomosis (RCA), which is newly called stage 4.[@b2-opth-6-1385] RAP is well known to have a different natural course and response to therapies as compared with typical exudative age-related macular degeneration.[@b3-opth-6-1385]--[@b5-opth-6-1385]

Retinal-retinal anastomosis (RRA) and RCA are important signs of RAP lesions.[@b1-opth-6-1385],[@b2-opth-6-1385] RRA and RCA contribute to a high blood supply to RAP lesions. Surgical lysis of feeding arterioles and draining venules has been reported to eliminate blood flow to RAP lesions, causing resolution of intraretinal edema and flattening of retinal pigment epithelial detachment,[@b6-opth-6-1385] but recurrence of exudation occurs with recanalization or new development of retinal feeding and draining vessels.[@b7-opth-6-1385] Therefore, complete occlusion of the RRA or RCA is important for reducing RAP lesions.

Vascular endothelial growth factor (VEGF) is well known to be closely associated with choroidal neovascularization complexes.[@b8-opth-6-1385]--[@b10-opth-6-1385] The major clinical trials first reported that ranibizumab (Lucentis, Genentech Inc, South San Francisco, CA) was effective in improving visual acuity for patients with age-related macular degeneration.[@b11-opth-6-1385],[@b12-opth-6-1385] Intravitreal ranibizumab has become one of the evidence-based therapies for age-related macular degeneration all over the world.[@b13-opth-6-1385] Recently, anti-VEGF therapy using intravitreal ranibizumab or bevacizumab has been reported to be a useful treatment for improving or maintaining visual acuity for patients with RAP.[@b14-opth-6-1385],[@b15-opth-6-1385] Nevertheless, intravitreal bevacizumab injections could not achieve complete occlusion of feeder vessels in eyes with RAP.[@b16-opth-6-1385] We have reported in previous studies that combined photodynamic therapy with intravitreal bevacizumab or ranibizumab achieved complete occlusion of RRA on indocyanine green angiography.[@b17-opth-6-1385]--[@b19-opth-6-1385] However, no reports have clarified the angiographic results of RRA or RCA in detail after treatment.

The purpose of the current study was to show the angiographic results of RRA or RCA after three consecutive monthly intravitreal bevacizumab injections or combined treatment of intravitreal bevacizumab and photodynamic therapy for eyes with RAP.

Materials and methods
=====================

We retrospectively reviewed five consecutive eyes from four Japanese patients (two men, two women, mean age 80.0 ± 4.8, range 64--90 years) with naïve RAP treated using intravitreal bevacizumab as initial therapy from August to December 2006 at different stages of the disease. The patients were followed up for at least 3 months at Fukushima Medical University Hospital. The exclusion criteria were previous treatment for RAP, such as laser photocoagulation, submacular surgery, transpupillary thermotherapy, photodynamic monotherapy, or a combination of photodynamic therapy with intravitreal triamcinolone acetonide, and maculopathies, such as diabetic maculopathy, retinal vascular occlusion, or idiopathic macular telangiectasia.

The institutional review board/ethics committee at Fukushima Medical University approved the bevacizumab, retrospective chart review of patients with age-related macular degeneration, and retrospective comparative analysis performed in this study. After the potential risks and benefits were explained in detail, all patients provided their written informed consent.

We used best-corrected visual acuity (BCVA) measured using a standard Japanese decimal visual acuity chart and calculated the mean BCVA using the logarithm of the minimum angle of resolution (logMAR) scale. We converted decimal BCVA into Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity letter scores using a previously reported mathematical method.[@b20-opth-6-1385],[@b21-opth-6-1385] All patients underwent a standardized examination, including slit-lamp biomicroscopy with a contact lens, color or red-free fundus photography, fluorescein angiography, indocyanine green angiography with a fundus camera (TRC-50 FA/IA/IMAGEnet H1024 system, Topcon, Tokyo, Japan), and confocal scanning laser ophthalmoscopy (Heidelberg Retina Angiograph 2, Heidelberg Engineering, Heidelberg, Germany). All optical coherence tomography (OCT) examinations were performed using spectral-domain optical coherence tomography (3D-OCT, Topcon, Tokyo, Japan). Fluorescein angiography was performed to determine the lesion type, location, and choroidal neovascularization activity of the RAP lesions, ie, the degree or extent of leakage. Indocyanine green angiography was performed to diagnose RAP and identify RRA and RCA.

All patients had documented visual loss at baseline. The method used to administer intravitreal bevacizumab (1.25 mg/0.05 mL) was according to past reports.[@b17-opth-6-1385],[@b18-opth-6-1385] After the three monthly intravitreal bevacizumab injections, fluorescein and indocyanine green angiography was performed for all eyes. In cases with over 3 months of follow-up and having recurrence of RAP or leakage on fluorescein angiography, we performed retreatment with a single intravitreal bevacizumab injection and photodynamic therapy, as reported previously.[@b17-opth-6-1385],[@b18-opth-6-1385]

Statistical analysis was performed using the Student's paired *t*-test to compare visual acuity at one and 3 months after treatment. *P* values ≤ 0.05 were considered to be statistically significant. We used logMAR visual acuity scores for the statistical analysis.

Results
=======

[Table 1](#t1-opth-6-1385){ref-type="table"} shows the characteristics and clinical data for the consecutive four patients (representing five eyes). All patients were Japanese and were observed for at least 3 months (range 4--10 months, mean 7.4 ± 2.2 months). One eye had stage 2 RAP without retinal pigment epithelial detachment, two eyes had stage 2 RAP with pigment epithelial detachment, and two eyes had stage 3 RAP.

Early-phase indocyanine green angiography identified RRA in three eyes and RCA in two eyes at baseline ([Figures 1](#f1-opth-6-1385){ref-type="fig"} and [2](#f2-opth-6-1385){ref-type="fig"}). At month 3, neither the RRA nor RCA was occluded in any of the eyes ([Table 1](#t1-opth-6-1385){ref-type="table"}, [Figures 1](#f1-opth-6-1385){ref-type="fig"} and [2](#f2-opth-6-1385){ref-type="fig"}). Late-phase indocyanine green angiography showed a hot spot in all five eyes at baseline ([Table 1](#t1-opth-6-1385){ref-type="table"} and [Figure 1](#f1-opth-6-1385){ref-type="fig"}). The hot spot resolved completely in two eyes and decreased in three eyes at month 3 ([Table 1](#t1-opth-6-1385){ref-type="table"}). At baseline, all five eyes had cystoid macular edema and four eyes had pigment epithelial detachment on OCT. Cystoid macular edema resolved in two (40%) eyes at a mean of one week after baseline and decreased in three eyes ([Table 1](#t1-opth-6-1385){ref-type="table"}). The pigment epithelial detachment resolved in one (25%) eye 4 weeks after baseline and remained in three eyes ([Table 1](#t1-opth-6-1385){ref-type="table"}). At month 3, OCT showed cystoid macular edema remaining in the three eyes and the remaining pigment epithelial detachment in the one eye had decreased from baseline ([Table 1](#t1-opth-6-1385){ref-type="table"}).

Fluorescein angiography showed resolution of leakage in two (40%) of the five eyes at month 3. In the remaining three eyes, two eyes had minimal leakage and one eye had persistent leakage by fluorescein angiography.

Retreatment using intravitreal bevacizumab plus photodynamic therapy was performed in one eye with persistent leakage on fluorescein angiography at month 3 ([Table 1](#t1-opth-6-1385){ref-type="table"}). Two eyes with minimal leakage on fluorescein angiography showed decreased cystoid macular edema and unchanged pigment epithelial detachment at month 3; improving visual acuity was observed at this time and the patient did not consent to retreatment. In the remaining two eyes without a hot spot on indocyanine green angiography, leakage by fluorescein angiography, or exudation by OCT at month 3, indocyanine green angiography showed recurrence of the RAP lesion with exudation on OCT at months 6 and 7 ([Table 1](#t1-opth-6-1385){ref-type="table"}, [Figures 1](#f1-opth-6-1385){ref-type="fig"} and [2](#f2-opth-6-1385){ref-type="fig"}). Retreatment was performed with intravitreal bevacizumab plus photodynamic therapy in both eyes. Of the three eyes retreated with intravitreal bevacizumab plus photodynamic therapy, obvious resolution of RRA and RCA was seen on indocyanine green angiography in all three eyes 3 months after retreatment ([Figures 1](#f1-opth-6-1385){ref-type="fig"} and [2](#f2-opth-6-1385){ref-type="fig"}).

The mean decimal BCVA (logMAR equivalent, decimal value converted to an approximate ETDRS) levels at baseline and months 1 and 3 were 0.13 (0.89) (40), 0.22 (0.66) (52), and 0.21 (0.68) (51), respectively. There was no statistically significant difference in mean BCVA at months 1 and 3 (*P* = 0.058 and *P* = 0.066, respectively, paired *t*-test). The mean changes in BCVA at months 1 and 3 were improvements of 2.29 and 2.13 lines, respectively. Two (40%) of the five eyes showed an increase in BCVA of three or more lines, and three (60%) eyes had stable visual acuity (defined as a loss of less than three lines of vision) at month 3.

There were no complications, such as inflammation, intraocular pressure \> 21 mmHg, severe vision loss, endophthalmitis, progression of cataract, or systemic adverse events.

Discussion
==========

In the current study, intravitreal bevacizumab monotherapy for RAP could not achieve complete occlusion of RRA and RCA. Recurrence of the RAP lesion was also seen in a high percentage of cases. On the other hand, retreatment with intravitreal bevacizumab plus photodynamic therapy ultimately achieved complete occlusion of the RRA and RCA.

Although the natural history of RAP has been reported to be poor visual results,[@b22-opth-6-1385] there has been no evidence for treatment of patients with RAP based on the major clinical trials. Most treatments, including conventional laser photocoagulation,[@b23-opth-6-1385] transpupillary thermotherapy,[@b4-opth-6-1385] surgical ablation,[@b7-opth-6-1385] and photodynamic therapy alone[@b24-opth-6-1385] have not been effective for patients with RAP until now. Complete occlusion of RRA or RCA is important for reducing RAP lesions because of the high blood supply to these lesions. Surgical lysis of the feeding arterioles and draining venules to eliminate blood flow to RAP lesions can achieve temporary resolution of intraretinal edema and flattening of pigment epithelial detachment,[@b6-opth-6-1385] but recurrence of exudation occurs with recanalization or new development of retinal feeding and draining vessels.[@b7-opth-6-1385] In our study, disappearance of RRA and RCA by indocyanine green angiography could not be achieved in all eyes by month 3. On the other hand, retreatment consisting of intravitreal bevacizumab plus photodynamic therapy ultimately achieved complete occlusion of the RRA and RCA. We have reported in previous studies that intravitreal bevacizumab plus photodynamic therapy and combined intravitreal ranibizumab with photodynamic therapy can achieve complete occlusion of RRA in a high percentage of cases.[@b17-opth-6-1385]--[@b19-opth-6-1385] From these results, a combination of an anti-VEGF agent and photodynamic therapy may be superior to anti-VEGF alone for reducing the high blood supply to RAP lesions.

In the current study, we also performed photodynamic therapy one or 2 days after intravitreal bevacizumab injection, as in our previous studies[@b17-opth-6-1385],[@b18-opth-6-1385] for the following reasons. Anti-VEGF therapy in patients with RAP can rapidly resolve the intraretinal edema, hemorrhage, and neovascular lesions in clinical treatment.[@b18-opth-6-1385],[@b19-opth-6-1385] Rapid neovascular complex suppression in patients with RAP could be achieved after intravitreal anti-VEGF agents.[@b18-opth-6-1385],[@b19-opth-6-1385] We have hypothesized that verteporfin may accumulate minimally in a suppressed neovascular complex after injection of intravitreal anti-VEGF agents, and may be less effective.[@b18-opth-6-1385],[@b19-opth-6-1385]

The recommended treatment at present for age-related macular degeneration is ranibizumab, and bevacizumab is used off-label in these patients. Recently, CATT (the randomized Comparison of Age-Related Macular Degeneration Treatments Trials) showed that the effects of bevacizumab and ranibizumab on visual acuity at 24 months were equivalent.[@b25-opth-6-1385] Based on the results of the current study using bevacizumab monotherapy, we can infer the efficacy of ranibizumab monotherapy.

In animal models, overexpression of VEGF in the photoreceptors of the retina is sufficient to cause intraretinal and subretinal neovascularization,[@b26-opth-6-1385] which is similar to the neovascular process of RAP. Anti-VEGF monotherapy has been suggested on theoretical grounds. Recently, intravitreal anti-VEGF therapy using ranibizumab or bevacizumab has been reported to be useful for RAP.[@b14-opth-6-1385],[@b15-opth-6-1385] Gharbiya et al[@b14-opth-6-1385] reported the efficacy of three monthly intravitreal bevacizumab injections in 17 eyes with RAP, which showed significant improvement in visual acuity from 39.53 letters on the ETDRS chart (decimal equivalent 0.48) to 47.88 letters (0.71) at month 12. Twelve (70.6%) of the 17 eyes required additional injections during the 12-month follow-up period. Hemeida et al[@b15-opth-6-1385] reported 2-year results of anti-VEGF monotherapy using ranibizumab or bevacizumab for RAP. Repeat treatments were required in 75% of eyes and mean visual acuity at months 12, 18, and 24 showed no significant improvement. In addition, they concluded that anti-VEGF monotherapy might not be sufficient to maintain anatomical and functional improvement. In the current study, while the mean change in BCVA at month 3 was improvement of 2.13 lines, three (60%) of the five eyes showed persistent leakage on fluorescein angiography, cystoid macular edema, and pigment epithelial detachment on OCT at month 3. Most patients with anti-VEGF monotherapy need further injections during long-term follow up.

[Figures 1](#f1-opth-6-1385){ref-type="fig"} and [2](#f2-opth-6-1385){ref-type="fig"} show an apparent difference in angiographic results between intravitreal bevacizumab monotherapy and intravitreal bevacizumab plus photodynamic therapy. Indocyanine green angiography shows clearly that the RCA remained in spite of the resolving exudative lesions seen on red-free or OCT images. Moreover, the neovascular complex was obviously enlarged when recurrence of exudation was present, which eventually caused a decline in visual acuity. The poorer ability to achieve complete occlusion of the RRA or RCA using anti-VEGF agent monotherapy could be the main reason why more anti-VEGF injections were needed. On the other hand, the complete disappearance of RRA or RCA in a high percentage of cases after combined treatment using an anti-VEGF agent plus photodynamic therapy could reduce the number of treatments required, which may cause improvement or maintenance of visual acuity in the long term. Although two eyes in the current study showed minimal leakage on fluorescein angiography, cystoid macular edema, or pigment epithelial detachment at month 3, we continued to observe these patients because of their improving visual acuity and withdrawal of consent for retreatment. It might have been better if we had re-treated these patients with intravitreal bevacizumab plus photodynamic therapy, because they had persistent RRA, RCA, and a hot spot, and were therefore at high risk of recurrence. Because of the short follow-up durations involved, there was the potential for recurrence of the RAP lesion with RRA or RCA during further follow-up.

Conclusion
==========

Although intravitreal bevacizumab for RAP was effective in improving visual acuity during short-term follow-up, it could not achieve complete occlusion of RRA and RCA, so there was a risk of recurrence of the RAP lesion and exudates. On the other hand, retreatment consisting of intravitreal bevacizumab plus photodynamic therapy ultimately achieved complete occlusion of RRA and RCA. Because this was a small study with a short follow-up duration, larger and longer-term prospective randomized studies are needed to determine the angiographic efficacy of RRA or RCA after anti-VEGF therapy with or without photodynamic therapy in patients with RAP.

**Disclosure**

The authors have no proprietary interest in any aspect of this study and received no government funding.

![A 64-year-old woman was treated with intravitreal bevacizumab for stage 3 retinal angiomatous proliferation (RAP). At baseline, best-corrected visual acuity (BCVA) was 0.1 decimal visual acuity in the left eye. (**A**) Red-free photograph showing intraretinal and preretinal hemorrhages, drusen, retinal pigment epithelial detachment, and lipid. (**B**) Fluorescein angiography showing minimal classic choroidal neovascularization and intraretinal edema. (**C**) Early-phase indocyanine green angiography showing RAP lesions within the retina and beyond as well as retinal-choroidal anastomosis (RCA). (**D**) Late-phase indocyanine green angiography showing RAP lesions as focal areas of intense hyperfluorescence (hot spots) and staining of fibrin in cystoid spaces. (**E**) Baseline horizontal optical coherence tomography (OCT) image shows cystoid macular edema and a pigment epithelial detachment. (**F**) At month 3, after three consecutive monthly intravitreal bevacizumab injections, no hemorrhages, pigment epithelial detachment, or decreased lipid content are visible on a red-free photograph. BCVA improved from 0.1 to 0.2 decimal visual acuity. (**G**) No leakage or pigment epithelial detachment are seen on fluorescein angiography. (**H** and **I**) Indocyanine green angiography shows decreased leakage from RAP lesions, but RCA and neovascular complex remain. (**J**) OCT showing disappearance of edema and pigment epithelial detachment. No additional treatment was performed. (**K**) Red-free photograph at month 6 shows recurrence of intraretinal and preretinal hemorrhages, edema, and pigment epithelial detachment. BCVA decreased from 0.2 to 0.1 decimal visual acuity at month 3. (**L**) Fluorescein angiography shows enlargement of leakage and pigment epithelial detachment. (**M**) Early-phase indocyanine green angiography shows enlargement of the neovascular complex and thickening of the RCA. (**N**) No hot spot was seen on late-phase indocyanine green angiography. (**O**) OCT shows severe edema and expansion of pigment epithelial detachment. We retreated with intravitreal bevacizumab plus photodynamic therapy instead of intravitreal bevacizumab. (**P**) Three months after intravitreal bevacizumab plus photodynamic therapy (month 9), a red-free photograph shows disappearance of intraretinal and preretinal hemorrhages, edema, and pigment epithelial detachment. (**Q** and **S**) Fluorescein and late-phase indocyanine green angiography showing no leakage. (**R**) Early-phase indocyanine green angiography showing complete disappearance of RCA. (**T**) Horizontal OCT image shows flattening of the neurosensory retina. BCVA was 0.2 decimal visual acuity.](opth-6-1385f1){#f1-opth-6-1385}

![Magnification of early-phase indocyanine green angiography images from [Figure 1](#f1-opth-6-1385){ref-type="fig"} at baseline (**A**), and months 3 (**B**), 6 (**C**), and 9 (**D**). (**A**--**C**) This patient with stage 3 retinal angiomatous proliferation had proliferation within the retina (arrowheads) consisting of a preperfusing (arrows) and a draining (outline arrows) retinal vessel communicating with the area of choroidal neovascularization (outline arrowheads). (**B** and **D**) Although retinal-choroidal anastomosis (RCA) persisted after three consecutive monthly intravitreal bevacizumab injections, it finally resolved after combined therapy of intravitreal bevacizumab and photodynamic therapy.](opth-6-1385f2){#f2-opth-6-1385}

###### 

Clinical profiles of patients

  Case no   Age (years)   Gender   Eye     RAP stage   Baseline           Month 3   From month 3 onwards                                                                           
  --------- ------------- -------- ------- ----------- ------------------ --------- ---------------------- ------------------ ----- ---- ---- ---- --------- --------------------- ----
  1         64            F        Left    3           0.1 (1.00) (35)    RCA       Yes                    0.2 (0.70) (50)    Yes   Di   Di   No   No        IVB + PDT (month 6)   No
  2         89            M        Left    2 + PED     0.1 (1.00) (35)    RRA       Yes                    0.3 (0.52) (58)    Yes   De   NC   De   Minimal   No                    --
  3         77            M        Right   2           0.3 (0.52) (58)    RRA       Yes                    0.5 (0.30) (70)    Yes   Di   --   No   No        IVB + PDT (month 7)   No
  4         90            F        Right   3           0.06 (1.22) (24)   RCA       Yes                    0.07 (1.15) (27)   Yes   De   NC   De   Minimal   No                    --
  5         90            F        Left    2 + PED     0.2 (0.70) (50)    RRA       Yes                    0.2 (0.70) (50)    Yes   De   De   De   Yes       IVB + PDT (month 3)   No
  Mean      80.0                                       0.13 (0.89) (40)                                    0.21 (0.68) (51)                                                        

**Abbreviations:** F, female; M, male; RAP, retinal angiomatous proliferation; ETDRS, Early Treatment Diabetic Retinopathy Study; VA (logMAR) (ETDRS), decimal visual acuity (logMAR equivalent) (convert decimal value to an approximate ETDRS); RRA, retinal-retinal anastomosis; RCA, retinal-choroidal anastomosis; CME, cystoid macular edema; PED, pigment epithelial detachment; FA, fluorescein angiography; PDT, photodynamic therapy; Di, disappeared; De, decreased; NC, no change; IVB, intravitreal bevacizumab injection; PDT, photodynamic therapy.